PCH
ARQT icon

Polar Capital Holdings’s Arcutis Biotherapeutics ARQT Stock Holding History

Polar Capital Holdings’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$173M Buy
6,606,945
+940,005
+17% +$21.9M 0.41% 57
2026
Q1 		$134M Buy
5,666,940
+110,771
+2% +$2.83M 0.47% 54
2025
Q4 		$161M Buy
5,556,169
+257,415
+5% +$6.59M 0.62% 41
2025
Q3 		$99.9M Buy
5,298,754
+292,279
+6% +$4.61M 0.48% 60
2025
Q2 		$70.2M Sell
5,006,475
-1,700,000
-25% -$23.8M 0.37% 71
2025
Q1 		$105M Sell
6,706,475
-670,906
-9% -$9.45M 0.64% 45
2024
Q4 		$103M Buy
7,377,381
+493,009
+7% +$5.4M 0.57% 50
2024
Q3 		$64M Buy
6,884,372
+5,300
+0.1% +$52.3K 0.31% 69
2024
Q2 		$64M Sell
6,879,072
-6,850
-0.1% -$61.9K 0.38% 71
2024
Q1 		$68.2M Buy
6,885,922
+588,234
+9% +$4.39M 0.36% 70
2023
Q4 		$20.3M Buy
6,297,688
+3,179,744
+102% +$8.64M 0.12% 133
2023
Q3 		$16.6M Sell
3,117,944
-9,833
-0.3% -$83.6K 0.12% 150
2023
Q2 		$29.8M Sell
3,127,777
-7,736
-0.2% -$85.9K 0.15% 121
2023
Q1 		$34.5M Buy
3,135,513
+1,129,736
+56% +$16.3M 0.22% 108
2022
Q4 		$29.7M Buy
2,005,777
+696,509
+53% +$12.2M 0.24% 116
2022
Q3 		$25M Sell
1,309,268
-96,528
-7% -$2.19M 0.16% 122
2022
Q2 		$30M Sell
1,405,796
-378,209
-21% -$7.76M 0.18% 113
2022
Q1 		$34.4M Hold
1,784,005
– – 0.16% 118
2021
Q4 		$37M Buy
1,784,005
+235,104
+15% +$4.68M 0.14% 122
2021
Q3 		$37M Sell
1,548,901
-133,642
-8% -$3.05M 0.15% 120
2021
Q2 		$45.9M Buy
1,682,543
+125,000
+8% +$3.52M 0.2% 107
2021
Q1 		$45.1M Buy
1,557,543
+782,543
+101% +$24.4M 0.28% 94
2020
Q4 		$21.8M Buy
+775,000
New +$19M 0.13% 149

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Polar Capital Holdings's ARQT Position: Q2 2026 in Review

Polar Capital Holdings increased its Arcutis Biotherapeutics (ARQT) stake by 17% in Q2 2026, buying an estimated $21.9M and bringing the position to 6,606,945 shares worth $173M. The position accounts for 0.41% of the portfolio, ranked #57.

Polar Capital Holdings first reported a position in ARQT in Q4 2020 and has held it in 23 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Polar Capital Holdings held 6,606,945 shares of Arcutis Biotherapeutics worth $173M as of Q2 2026.
  • Polar Capital Holdings bought 940,005 Arcutis Biotherapeutics shares in Q2 2026, an estimated $21.9M.
  • Arcutis Biotherapeutics made up 0.41% of Polar Capital Holdings's portfolio in Q2 2026, its #57 holding.
  • Polar Capital Holdings first reported a position in Arcutis Biotherapeutics in Q4 2020 and has held it in 23 quarters since.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Polar Capital Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.